Can Veeva Systems Inc. (VEEV)’s AI Platform Keep Pace With Eli Lilly and Company (LLY)’s Explosive Growth
On August 11, Veeva Systems Inc. (VEEV) disclosed that Eli Lilly and Company (LLY) would deploy Veeva Vault CRM globally. Vault CRM serves as the foundation for Veeva's AI-driven commercial framework, enhancing field engagement and expediting medicine delivery. Although VEEV operates as an enterprise software provider, LLY functions as a pharmaceutical manufacturer.
Despite differing business models, their partnership underscores the growing synergy between technology and drug development. VEEV reported $882.9 million in total revenue for its Fiscal 2027 First Quarter (ended April 30, 2026), a 16% year-over-year increase, primarily from $730.2 million in subscription revenue (15% growth). Non-GAAP EBIT reached $395 million, resulting in an operating margin above 44%.
Meanwhile, LLY's Q2 2026 revenue surged 48% year-over-year to $22.97 billion, bolstered by high demand for GLP-1 therapies Mounjaro and Zepbound. Non-GAAP net income increased 32% to $7.49 billion, or $8.38 per share. LLY heightened its full-year 2026 revenue guidance to $85.0–$87.0 billion, indicating robust operational momentum despite absorbing $3.03 per share in acquired R&D costs.
On August 7, Truist increased its price target on LLY to $1,376 with a Buy rating, attributing the move to substantial incretin volume growth offsetting pricing pressures. On August 10, the UK's MHRA approved Lilly's GLP-1 pill Foundayo, the first daily oral option for weight management and type 2 diabetes without food or water restrictions.
The latest Insider Monkey hedge fund data shows a slight decline in institutional participation in both equities, with VEEV held by 62 funds in Q1 2026, down from 75 in Q4 2025. Among top holders, Zevenbergen Capital Investments saw a 5% decrease, while Long Path Partners increased activity by 61%. Conversely, LLY was held by 132 funds in Q1 2026, with Fisher Asset Management increasing its stake by 5%.
Both companies showcase strong fundamentals in their respective industries, with VEEV offering high-margin SaaS growth and LLY delivering growth through blockbuster GLP-1 therapies. Investors should monitor VEEV's global Vault CRM rollouts and AI platform monetization, while LLY's clinical breakthroughs and regulatory approvals are key catalysts.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
